Obesity is associated with the development of asthma, which is often difficult to control. To understand the immunological pathways that lead to obesity-associated asthma, we fed mice a high-fat diet for 12 weeks, which resulted in obesity and the development of airway hyperreactivity (AHR), a cardinal feature of asthma. This AHR was independent of adaptive immunity, as it occurred in obese Rag1 −/− mice, which lack B and T cells, and was dependent on interleukin-17A (IL-17A) and the NLRP3 inflammasome, as it did not develop in obese Il17a −/− or Nlrp3 −/− mice. AHR was also associated with the expansion of CCR6 + type 3 innate lymphoid cells (ILCs) producing IL-17A (ILC3 cells) in the lung, which could by themselves mediate AHR when adoptively transferred into Rag2 −/− ; Il2rg −/− mice treated with recombinant IL-1b. Macrophage-derived IL-1b production was induced by HFD and expanded the number of lung ILC3 cells. Blockade of IL-1b with an IL-1 receptor antagonist abolished obesity-induced AHR and reduced the number of ILC3 cells. As we found ILC3-like cells in the bronchoalveolar lavage fluid of individuals with asthma, we suggest that obesity-associated asthma is facilitated by inflammation mediated by NLRP3, IL-1b and ILC3 cells. npg
The prevalence of obesity in industrialized countries has increased over the last two decades, such that obesity now affects 36% of all adults in the United States (66% of all adults are classified as overweight or obese) 1 . Chronic complications from obesity include type 2 diabetes mellitus, cardiovascular disease, liver disease and some forms of cancer 2 . Recent studies have also shown that obesity is a major risk factor for the development of asthma [3] [4] [5] . Although obesity itself can alter lung mechanics independently of asthma, the incidence of asthma increases with body mass index (BMI) in both men and women, in children and adults and across multiple racial backgrounds 4 . Substantial weight loss in obese individuals with asthma can lead to considerable improvement of asthma symptoms, which reinforces the relationship between obesity and asthma 6 . Unfortunately, obese individuals with asthma respond poorly to typical asthma medications, including corticosteroids, leading to greater asthma-related healthcare utilization and reduced quality of life 3, 7 . The lack of effective therapies for asthma in obese individuals might reflect the poor understanding of the specific immunological and metabolic mechanisms by which nutritional excess and adiposity lead to asthma 8,9 . Although the mechanisms that cause asthma in the face of nutritional excess remain undefined, obesity is widely recognized as a cause of chronic inflammation that leads to type 2 diabetes, atherosclerosis and liver disease 10 . Immunologically, obesity is associated with a reduction in anti-inflammatory regulatory T cells 11 , an increase in CD8 + T cells 12 and a transition in macrophage polarization from M2 to M1 in adipose tissue 10, 13 . In the lungs, however, the role of inflammation in obesity has been controversial, as little correlation of airway eosinophils with BMI has been observed, although increases in the number of sputum neutrophils in obese individuals with asthma have been reported recently 14 . Increased circulating levels of adipokines (leptin, adiponectin and resistin), IL-6, tumor necrosis factor-α (TNF-α) and oxidative stress 3, 8 are all associated with asthma in obese individuals but not with allergic asthma, the most common form of asthma. Moreover, the association between asthma and obesity is stronger in individuals with nonatopic asthma than in those with atopic asthma 15 , and weight loss reduces AHR in obese individuals with nonatopic asthma but not in those with the atopic form 6 . These observations suggest that asthma associated with obesity is an entity or phenotype distinct from that of allergic asthma 16 .
To clarify the mechanisms by which obesity might cause asthma, we examined a mouse model of diet-induced obesity. Our results using this model demonstrate a previously undescribed molecular and cellular pathway for the development of obesity-induced asthma and suggest specific therapeutic modalities for this growing clinical problem.
RESULTS

High-fat diet results in obesity and AHR
We studied airway disease in wild-type (WT) mice fed a high-fat diet (HFD) for 14 weeks starting at 3-4 weeks of age. On a HFD, mice gained weight rapidly ( Fig. 1a) and developed hepatic steatosis and increased epididymal fat volumes compared to control mice on a standard chow diet ( Fig. 1b) . Notably, the obese mice on the HFD developed AHR (Fig. 1c) , whereas mice on the standard diet had normal airway reactivity. Similarly, leptin-deficient ob/ob mice, which rapidly developed obesity on the standard chow diet, also developed AHR ( Fig. 1d) , as previously reported 17, 18 . These results demonstrate that diet-induced obesity and obesity associated with leptin deficiency are both associated with the development of AHR.
IL-17A is required for HFD-induced AHR As obesity-associated AHR is not linked strongly with atopy 18 , we asked whether it is dependent on IL-17A. Indeed, IL-17A production was greatly increased in the lungs of the obese mice, as assessed in cultured lung cells ( Fig. 2a) . Moreover, Il17a −/− mice on the HFD developed obesity ( Fig. 2b ) but failed to develop obesity-associated AHR ( Fig. 2c) , indicating that AHR requires IL-17A. In the lungs of the obese WT mice, Il17a mRNA levels were significantly increased in both CD4 − and CD4 + lymphocyte fractions (which included both T and non-T cells) ( Fig. 2d) . The major producers of IL-17A in the lungs of both obese WT and ob/ob mice were non-T non-B CD4 − lineagenegative (Lin − ) cells, which are characteristics of type 3 ILCs that produce IL-17A (ILC3 cells) [19] [20] [21] [22] (Fig. 2e) , although some Lin + cells (for example, CD4 + T helper type 17 (T H 17) cells and γδ T cells) also produced IL-17A ( Supplementary Fig. 1) . The ILC3-like cells expressed high levels of Thy1.2, Sca-1, retinoic acid-related orphan receptorγ t (RORγt) and CD44, but not c-Kit (Fig. 2f) , and did not produce IL-13 ( Supplementary Fig. 1 ), suggesting these cells share features with IL-17 + ILC3 cells previously described in the intestines of mice and humans in the setting of inflammatory bowel disease 19, 20 and are distinct from lymphoid tissue inducer (LTi) ILC3 cells [23] [24] [25] , IL-22 + ILC3 cells 26, 27 and lung ILC2 cells (also called nuocytes or natural helper cells), which produce IL-13 and IL-5 and express variable amounts of c-Kit [28] [29] [30] [31] .
To better understand the role of T H 17 and ILC3 cells in HFDinduced AHR, we placed Rag1 −/− mice on the HFD for 12 weeks before assessing AHR. Obese Rag1 −/− mice, which develop type 2 diabetes presumably through mechanisms that are independent of adaptive immunity and T H 17 cells 32 , also developed AHR associated with an increase in the lungs of ILC3 cells expressing IL-17, CCR6 and RORγt but little T-bet ( Fig. 2g,h) or IL-22 and no interferon-γ (IFN-γ) ( Supplementary Fig. 1 ). This suggests that ILC3 cells were sufficient for the development of pulmonary inflammation and AHR in the obese mice and that T H 17 cells or γδ T cells were not required. Consistent with this idea, C57BL/6 mice from both The Jackson Laboratory and Taconic Farms developed obesity-induced AHR and an increase in IL-17 + ILC3 cells ( Supplementary Fig. 2) , despite the fact that segmented filamentous bacteria (SFB), which is essential for the development of T H 17 cells 33, 34 , were detected only in the stools of mice obtained from Taconic Farms fed either the HFD or normal chow (data not shown) 33 . Together, these results demonstrate for the first time (to our knowledge) that ILC3 cells are present in the lungs and suggest that ILC3 cells, which could develop in the absence of SFB, might have a key pathogenic role in airway disease.
Inflammation in lungs of obese mice requires NLRP3
We examined the expression of other cytokines in the lungs and adipose tissue of obese mice and found that Il1b, Il6 and Il23 mRNA (known to induce IL-17A production in T H 17 cells) 35 were increased in the lungs and adipose tissue of the obese mice, as determined by RT-PCR ( Fig. 3a-f ). The inflammatory cells in the lungs and adipose tissue included macrophages, particularly M1 (F4/80 + CD11c + CD206 − ) macrophages, although total numbers of M2 macrophages (F4/ 80 + CD206 + ) in both tissues were also slightly increased after 12 weeks on the HFD ( Fig. 3g and Supplementary Fig. 3 ). Moreover, M1 macrophages, and to a much lesser extent M2 macrophages, from obese WT mice and obese ob/ob mice expressed IL-1β, as determined by intracellular cytokine staining ( Supplementary Fig. 3 and Fig. 3h ). In addition, in the lungs and adipose tissue of mice on the HFD, there was a reduction in the number of regulatory T cells (Supplementary Fig. 3 ) and natural killer T cells (data not shown), as previously reported 11, 36 .
As adipose tissue macrophages in obese mice have been shown to produce IL-1β in an inflammasome-dependent manner 37,38 , we examined Nlrp3 mRNA expression in the lungs and found that it was increased, as it was in the liver and adipose tissues of obese mice ( Fig. 4a) . Moreover, NACHT, leucine-rich repeat and pyrin npg domain-containing protein 3 (NLRP3) was required for obesityinduced AHR, as Nlrp3 −/− mice fed the HFD rapidly gained weight, developed some degree of hepatic steatosis and had increased adipose tissue volumes (Fig. 4b,c ) but failed to develop AHR ( Fig. 4d) . Further, Nlrp3 −/− mice on a HFD did not have increased lung IL-1β production ( Fig. 4e) and had a significantly reduced number of pulmonary ILC3 cells compared to obese WT mice ( Fig. 4f) . In contrast, the number of Lin + IL-17 + (T H 17 and γδ T cells) cells was only slightly increased in the lungs of obese WT and Nlrp3 −/− mice compared to the chow-fed WT and Nlrp3 −/− mice, respectively ( Fig. 4f) , which supports the idea that T H 17 cells were not required for the development of obesity-associated AHR. Therefore, the development of AHR in obese mice is associated with the activation of NLRP3, the production of IL-1β and the expansion of IL-17 + ILC3 cells in the lungs.
IL-1b directly causes AHR by inducing IL-17A production
We hypothesized that in obese mice, IL-1β produced by lung macrophages induced the development of ILC3 cells in a process that was independent of adaptive immunity. Indeed, the administration of recombinant IL-1β (rIL-1β) into the lungs of Rag2 −/− mice rapidly induced a robust AHR response ( Fig. 5a ). Treatment of Rag2 −/− mice with rIL-1α and rIL-23 but not rIL-6 also resulted in the development of AHR, although the effect with IL-23 was not as robust as with IL-1β ( Fig. 5b and Supplementary Fig. 3) . The IL-1β-induced AHR response required ILC3 cells, as it was abolished by depletion of ILC3 cells by in vivo treatment with a Thy1.2-specific monoclonal antibody (mAb) ( Fig. 5c) , which reduced the number of ILC3 cells ( Fig. 5d ) and resulted in a decrease in the number of inflammatory cells in the bronchoalveolar lavage (BAL) fluid of IL-1β− mice and Thy1.2 mAb-treated mice (Fig. 5c) . The IL-1β treatment induced IL-17A-producing ILCs that expressed CCR6 but only low levels of IL-17F, granulocyte-macrophage colony-stimulating factor (GM-CSF) or T-bet, as shown by intracellular staining (Supplementary Fig. 4 ). Furthermore, treatment with IL-1β induced AHR and IL-17 production in ILCs in Nlrp3 −/− , Il6 −/− and Tcrd −/− mice (lacking γδ T cells), but not in Rorc −/− mice (lacking RORγt) ( Supplementary Fig. 5 ), indicating that ILC3 cells required RORγt but could develop and induce AHR in the absence of NLRP3, IL-6 or γδ T cells. Moreover, ILC3 cells by themselves were sufficient for the development of AHR, as adoptive transfer of the ILC3 cells (Lin − CCR6 npg mice restored IL-1β-induced AHR (Fig. 5e,f) . The induction of AHR and airway inflammation by rIL-1β required cells producing IL-17A but not IL-4 or IL-13 (for example, T H 2 or ILC2 cells), as treatment of Il4 −/− ; I13 −/− mice but not Il17a −/− mice with rIL-1β resulted in AHR ( Fig. 5g) . Although treatment of WT mice with rIL-17A alone induced only minimal or no AHR ( Supplementary Fig. 6 ), treatment of Il17a −/− mice with both rIL-1β and rIL-17A resulted in AHR and airway inflammation ( Supplementary Fig. 6 ), confirming a critical role for IL-17A in IL-1β-induced AHR. Further, administration of rIL-1β to Rorc −/− mice failed to induce AHR, and IL-17A-specific mAb administration blocked IL-1β-induced AHR in Rag1 −/− mice ( Supplementary Fig. 6) , confirming a need for ILC3 cells (which require Rorc for development 31 ) and IL-17A in the development of IL-1β-induced AHR. Finally, ILC3 cells directly respond to IL-1β as ILC3 cells taken from IL-1β-treated Rag2 −/− mice express IL-1R ( Fig. 5h) and produce more IL-17 when cultured in vitro with rIL-1β npg (along with IL-7 and IL-2) ( Fig. 5i) . Although IL-23 in the lungs of obese mice might contribute to ILC3 cell expansion, these studies indicate that IL-1β can induce AHR independently of adaptive immunity, IL-4 or IL-13 by expanding lung ILC3 cells, which can directly cause AHR.
Blockade of IL-1b signaling prevents obesity-induced AHR
We confirmed the role of IL-1β in HFD-induced AHR by blocking IL-1β signaling using an IL-1 receptor antagonist (IL-1Ra; anakinra), which has previously been shown to improve hyperglycemia in obesity-induced type 2 diabetes in humans 39 . Treatment of obese mice fed a HFD for 13 weeks with anakinra for the last 7 d of this treatment abolished AHR (Fig. 6a,b) and reduced the number of pulmonary ILC3 cells (Fig. 6c) . These results indicate that chronic inflammation in obese mice triggers IL-1β production in the lung (presumably through NLRP3), which probably drives the expansion of ILC3 cells and the development of obesity-induced AHR.
Human ILC3 cells in the lungs of patients with asthma ILC3 cells have not been shown previously to be present in human lungs. However, in ten individuals with pulmonary disease, BAL fluid samples ( Supplementary Table 1 ) contained substantial, numbers of ILCs npg (Lin − IL-7R + cells), many of which expressed IL-17 ( Supplementary  Table 1 and Supplementary Fig. 7) . The Lin − IL-17 + cells appeared to be comparable in terms of marker expression and cytokine production tomouse ILC3 cells (Supplementary Fig. 7) , and patients with severe asthma had more of these cells than patients with mild asthma or no asthma (2.1% versus 0.2% of lymphocytes in the BAL fluid, P = 0.013) (Supplementary Table 1) . In vitro culture of BAL fluid cells from patients with asthma with rIL-1β (along with IL-7 and IL-2) also increased the number of IL-17-producing Lin − cells (Fig. 6d) . These studies demonstrate that IL-17-producing ILCs can be found in the lungs of humans and could potentially have a pathological role in asthma.
DISCUSSION
In these studies, we showed that in mice diet-induced obesity leads to the development of AHR through a pathway that requires NLRP3 and IL-17 and that is facilitated by pulmonary IL-17 + ILC3 cells, a cell type that has not been linked previously with airway disease (Fig. 6e) . AHR did not develop in obese Nlrp3 −/− mice or in obese Il17a −/− mice and was associated with IL-1β production by lung M1 macrophages in both obese mouse strains. Furthermore, IL-17 + ILC3 cells could by themselves induce AHR, as in vivo treatment of Rag2 −/− mice with rIL-1β rapidly induced the expansion of airway ILC3 cells and the development of AHR, and adoptive transfer of CCR6 + ILC3 cells into Rag2 −/− ; Il2rg −/− mice restored IL-1β−induced AHR. These results suggest that obesity-induced AHR develops through a unique pathway that involves an ILC3− IL-1β−NLRP3 inflammasome axis that is activated in the lungs in the face of nutritional excess 37, 38, 40 . Indeed, treatment of obese mice with IL-1R antagonist anakinra abolished AHR associated with HFD-induced obesity, suggesting obesity-induced airway inflammation and AHR is driven by IL-1β and mediated by an expanded population of pulmonary IL-17 + ILC3 cells.
The association between obesity and asthma has been known for several years 5 , but the specific mechanisms by which obesity causes asthma have been undefined until now. Although obesity in mice has been shown to induce AHR 41, 42 , enhance allergen-induced AHR 43, 44 and enhance ozone-induced AHR 17 , and although obesity has been recognized as an inflammatory disease that causes type 2 diabetes, atherosclerosis and liver disease 10 , the precise mechanisms that link obesity with airway inflammation and AHR have not been understood. We now suggest that the inflammation in obesity, which has been recently shown to arise from NLRP3 activation and excess production of 38, 40) , also underlies the development of asthma that is associated with obesity. npg In diet-induced obese WT and Rag −/− mice and in leptin-deficient obese ob/ob mice, we demonstrated the presence of a considerable increase in pulmonary IL-17 + ILC3 cells. A pathogenic role for the ILC3 cells in the lungs was demonstrated by the rapid increase in the number of lung ILC3 cells in Rag2 −/− mice treated with IL-1β or IL-1α, which was associated with the development of AHR, and was suggested by the expansion of ILC3 cells in obese Rag1 −/− mice that developed AHR. Although T H 17 cells, which can cause airway inflammation and AHR [45] [46] [47] [48] , and γδ T cells producing IL-17, which can inhibit the development of AHR 49 , were also present in the lungs of WT obese mice, ILC3 cells greatly outnumbered the T H 17 and γδ T cells in these mice and were absent in obese Rag1 −/− mice and in Rag2 −/− mice treated with IL-1β, both of which developed AHR. In addition, mice obtained from either Taconic Farms (which contain SFB) or The Jackson Laboratory (lacking SFB) 33 developed obesity-induced and IL-1β-induced AHR, which supports the idea that IL-17 + ILC3 cells and HFD-induced AHR could develop independently of both T H 17 cells and SFB (required for the development of T H 17 cells). Moreover, AHR induced by IL-1β required RORγt, as it failed to develop in Rorc −/− mice, and occurred independently of IL-4 and IL-13 in Il4 −/− ; Il13 −/− mice. These results indicate that ILC3 cells could function independently of ILC2 cells, which produce IL-13 and IL-5 and cause AHR during influenza infection 28 or airway inflammation in response to protease-containing allergens 29 . Additionally, the ILC3 cells associated with AHR produced little or no IL-17F, IL-22, GM-CSF or IFN-γ, which is consistent with previous studies showing that IL-17, but not IL-17F or IL-22, can induce AHR 45 and which suggests that IL-17F, IL-22 and IFN-γ have little or no role in inducing obesity-associated AHR. Furthermore, we confirmed that IL-17 + ILC3 cells, which developed in Il6 −/− mice, express the IL-1 receptor and respond to IL-1β (and IL-1α), as was previously shown in studies of intestinal ILC3 cells 21 that promote the pathology in inflammatory bowel disease 19, 20 . Finally, adoptive transfer of CCR6 + ILC3 cells into Rag2 −/− ; Il2rg −/− mice restored IL-1β-induced AHR, indicating that ILC3 cells alone were sufficient for the development of AHR.
We also demonstrated the role of IL-1β in obesity-induced AHR by showing that treatment of obese mice for 7 d with the IL-1R antagonist anakinra abolished obesity-induced AHR, which failed to develop in Nlrp3 −/− mice. The fatty acid palmitate 37 , cholesterol crystals, lowdensity lipoprotein 38 and ceramide (generated from fatty acids) 40 , which are all increased in abundance during nutritional excess, can each activate NLRP3, resulting in increased IL-1β production. In obese mice, an important source of IL-1β is adipose tissue macrophages, which are thought to convert from M2 to M1 forms in association with the activation of NLRP3 and the adaptor protein ASC 40 . In the lungs of obese mice, we showed that NLRP3 is indeed activated and that M1 macrophages produced much of the IL-1β. Moreover, in both diet-induced and ob/ob obese mice, activation of this obesity-NLRP3-IL-1β pathway resulted in the expansion and activation of pulmonary IL-17 + ILC3 cells, which facilitated AHR. However, blocking IL-1 signaling with anakinra abolished this pathway, suggesting that in the lung, IL-1β may be particularly important in regulating IL-17 production, as has been shown in the skin 50 , although other factors such IL-23 may contribute to this process. This NLRP3-IL-1β inflammatory pathway, in addition to mediating type 2 diabetes mellitus, nonalcoholic liver disease and cardiovascular disease 10 , has a key role in autoinflammatory conditions, for example, cryopyrinassociated periodic syndromes (CAPS) 51 , suggesting that these metabolic diseases are in some respect autoinflammatory. Our studies suggest that obesity-induced AHR also has features of, and might be considered related to, autoinflammatory diseases.
Previous studies of the pathological role of IL-1β and NLRP3 in the development of asthma have generated conflicting results. However, in these studies, NLRP3 has been studied primarily in the context of allergic asthma [52] [53] [54] [55] [56] . Although part of this controversy has focused on the role of alum as an adjuvant that might activate NLRP3 during allergic sensitization, we focused on a nonallergic model of asthma and instead propose that the NLRP3 pathway has a critical role in the development of asthma associated with obesity by mediating the development of ILC3 cells that cause AHR.
Although ILC3 cells have been found in the intestines of humans with inflammatory bowel disease [19] [20] [21] [22] and at low frequencies in inflamed human tonsil 57 , they have not been found previously in the context of human lung disease or AHR. Nevertheless, our studies demonstrating that ILC3 cells producing IL-17 can induce the development of AHR in obese mice are consistent with clinical observations in humans showing an association of obesity with elevated systemic levels of IL-17 and IL-1β (refs. 58,59) , particularly in obese individuals with nonatopic asthma 18, 19 . A major role for IL-17 + ILC3 cells in asthma development, which are probably recruited to and expand in the lungs and may be somewhat resistant to corticosteroids, is also suggested by our studies showing that ILC3-like cells are present in the lungs of humans and that these cells respond to IL-1β. However, as the number of ILC3 cells varied considerably in the BAL fluid of the ten patients examined, the precise role of ILC3 cells in human lung disease, including asthma associated with obesity, will require clinical studies with much larger numbers of patients. In any case, our studies confirm that asthma is indeed heterogeneous and suggest that an obesity-associated asthma phenotype may exist that involves an NLRP3-IL-1β-ILC3 cell axis and is distinct from previously described pathways for asthma 3, 16, 60 .
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